



65 West Watkins Mill Road  
Gaithersburg, MD 20878  
tel: 240-632-0740  
fax: 240-632-0735  
[www.genvec.com](http://www.genvec.com)

**FOR IMMEDIATE RELEASE:**

**CONTACT:**

**Douglas J. Swirsky**  
**Chief Financial Officer**  
**(240) 632-5510**  
[dswirsky@genvec.com](mailto:dswirsky@genvec.com)

## **GENVEC ANNOUNCES FIRST QUARTER 2008 RESULTS CONFERENCE CALL**

**GAITHERSBURG, MD** – May 2, 2008 – GenVec, Inc. (Nasdaq: GNVC) announced that it will release financial results for the first quarter ended March 31, 2008 on Thursday, May 8, 2008 after market close. GenVec will hold a conference call at 10:00 a.m. EDT on Friday, May 9, 2008 to discuss the company’s first quarter results.

To listen to the live conference call, please dial 888-713-4218 (U.S. or Canada) or 617-213-4870 (international) and use access code 73552989. Participants may pre-register for the call anytime at: <https://www.theconferencingservice.com/prereg/key.process?key=PBWGY6RTV>. Pre-registrants will be issued a PIN number to use when dialing into the live call, which will provide quick access to the conference. An audio replay of the conference call will be available starting at 12:00 p.m. on May 9, 2008 through May 16, 2008. To listen to the audio replay, dial 888-286-8010 (U.S. or Canada) or 617-801-6888 (international) and use access code 98825947.

A live webcast of the conference call will be available on the Company’s website and will be archived for 30 days. To access the webcast or the replay, go to [www.genvec.com](http://www.genvec.com), click on “Investor Relations,” and click on “Webcasts and Data.”

### ***About GenVec***

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec’s lead product, TNFerade™, is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer with infusion 5-FU and radiation in non-resectable, locally advanced pancreatic cancer. Additional clinical trials are in progress in rectal cancer, head and neck cancer, and melanoma. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and influenza. Additional information about GenVec is available at [www.genvec.com](http://www.genvec.com) and in the company’s various filings with the Securities and Exchange Commission.

###